Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173508 | 1.00 | HSD17B10 (0.64) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 | |
| SCHEMBL321989 | 1.00 | HSD17B10 (0.64) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 | |
| SCHEMBL3660521 | 1.00 | — | — | |
| Tetraxetan SCHEMBL2017956 | 1.00 | HSD17B10 (0.64) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 | |
| Tetraxetan SCHEMBL18018 | 1.00 | HSD17B10 (0.64) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 | |
| SCHEMBL6744121 | 1.00 | HSD17B10 (0.64) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 | |
| SCHEMBL3503521 | 1.00 | HSD17B10 (0.64) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 | |
| Tetraxetan SCHEMBL2635294 | 1.00 | HSD17B10 (0.64) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 | |
| Tetraxetan SCHEMBL23647851 | 0.97 | HSD17B10 (0.61) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 | |
| Tetraxetan SCHEMBL15766009 | 0.97 | HSD17B10 (0.61) | HSD17B10SLC6A9ALDH1A1SMN1; SMN2STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704924-A1 | RADIONUCLIDE-LOADED NANOPARTICLES FOR FOCAL TISSUE ABLATION | TRANSLATIONAL AND FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC (US) | 2026-03-11 | — | — | EP | claimed |
| US-12329831-B2 | Radionuclide-loaded nanoparticles for focal tissue ablation | TRANSLATIONAL AND FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC (US) | 2025-06-17 | — | — | US | claimed |
| WO-2024226199-A1 | RADIONUCLIDE-LOADED NANOPARTICLES FOR FOCAL TISSUE ABLATION | RAIKA MEDICAL IMAGING INC. (US) | 2024-10-31 | — | — | WO | claimed |
| US-20240350684-A1 | RADIONUCLIDE-LOADED NANOPARTICLES FOR FOCAL TISSUE ABLATION | TRANSLATIONAL AND FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC | 2024-10-24 | — | — | US | claimed |
| EP-4704924-A1 | RADIONUCLIDE-LOADED NANOPARTICLES FOR FOCAL TISSUE ABLATION | TRANSLATIONAL AND FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-12329831-B2 | Radionuclide-loaded nanoparticles for focal tissue ablation | TRANSLATIONAL AND FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC (US) | 2025-06-17 | — | — | US | disclosed |
| CN-119684401-A | Compounds comprising a linker, a chelator, a ligand binding entity, methods of preparation and uses thereof | 赛诺哈勃药业（成都）有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2024226199-A1 | RADIONUCLIDE-LOADED NANOPARTICLES FOR FOCAL TISSUE ABLATION | RAIKA MEDICAL IMAGING INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| EP-4455159-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS WITH BIO-DISTRIBUTION MODIFIER | 3B Pharmaceuticals GmbH (DE) | 2024-10-30 | — | — | EP | disclosed |
| US-20240350684-A1 | RADIONUCLIDE-LOADED NANOPARTICLES FOR FOCAL TISSUE ABLATION | TRANSLATIONAL AND FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC | 2024-10-24 | — | — | US | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2020186328-A1 | CHELATORS AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-09-24 | — | — | WO | disclosed |
| EP-3206720-B1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | SCV GMBH (DE) | 2020-04-22 | — | — | EP | disclosed |
| US-20200061218-A1 | Albumin-Binding PSMA Inhibitors | CANCER TARGETED TECHNOLOGY LLC | 2020-02-27 | — | — | US | disclosed |
| WO-2018098390-A1 | ALBUMIN-BINDING PSMA INHIBITORS | CANCER TARGETED TECHNOLOGY LLC (US) | 2018-05-31 | — | — | WO | disclosed |
| US-20170327520-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | SCV GMBH (DE) | 2017-11-16 | — | — | US | disclosed |
| WO-2016058704-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | SCV GMBH (DE) | 2016-04-21 | — | — | WO | disclosed |
| US-6770020-B2 | NEUTRON CAPTURE THERAPY (NCT) USING GADOLINIUM DIETHYLENETRIAMINEPENTAACETIC ACID; TREATING GLIOBLASTOMAS, GLIOMAS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-08-03 | — | — | US | disclosed |
| US-20030049202-A1 | Method of using gadolinium neutron capture to treat cancers | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030049202-A1 | Method of using gadolinium neutron capture to treat cancers | NUCB2, MKI67, GMNN | HSD17B10 3436/4885SLC6A9 620/4885ALDH1A1 4571/4885 |
| US-20170327520-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | PTH1R, VDR, MEN1 | HSD17B10 3937/4885SLC6A9 703/4885ALDH1A1 4006/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | HSD17B10 3848/4885SLC6A9 2603/4885ALDH1A1 3906/4885 |
| US-20200061218-A1 | Albumin-Binding PSMA Inhibitors | PSMA1, ALB, PSMA2 | HSD17B10 3053/4885SLC6A9 562/4885ALDH1A1 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.